Colonic drug delivery: An updated review

AAPS PharmSci

Volumn 5, Issue 2, 2003, Pages

  Shareef, M Ajmal ^a   Khar, Roop K ^a   Ahuja, Alka ^a   Ahmad, Farhan Jalees ^a   Raghava, Swita ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Colonic drug delivery; Drug targeting; pH dependent release; Polysaccharides; Time dependent release

Indexed keywords

ACRYLIC ACID DERIVATIVE; AMINOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; AMYLOSE; BALSALAZINE; BUDESONIDE; CELECOXIB; CHITOSAN; CORTICOSTEROID; DEXAMETHASONE; DISULFIDE; ETHYL CELLULOSE; GLYCOSIDE; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; IPSALAZINE; OLSALAZINE; PANCREAS ENZYME; PECTIN; POLYMACON; POLYMER; POLYSACCHARIDE; POLYSTYRENE; PREDNISOLONE; PRODRUG; ROPIVACAINE; SALAZOSULFAPYRIDINE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; DRUG; PEPTIDE; PROTEIN;

ANGINA PECTORIS; ARTHRITIS; COLON; COLORECTAL CANCER; CROHN DISEASE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; GASTROINTESTINAL TRACT; HUMAN; NOCTURNAL ASTHMA; NONHUMAN; REVIEW; STOMACH PH; STRUCTURE ACTIVITY RELATION; ULCERATIVE COLITIS; CHEMISTRY; DIET; HISTOLOGY; INTESTINE ABSORPTION; METABOLISM; MICROBIOLOGY; PH; PHYSIOLOGY; STOMACH EMPTYING; TIME;

CHEMISTRY, PHARMACEUTICAL; COLON; DIET; DRUG DELIVERY SYSTEMS; GASTRIC EMPTYING; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; TIME FACTORS;

EID: 0347300800     PISSN: 15221060     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps050217     Document Type: Review

References (157)

1. Macheras P, Reppas C, Dressman JB. In: Biopharmaceutics of Orally Administered Drugs. Chichester, England: Ellis Horwood; 1989:7-22.
2. Steeds KP, Wilson CG, Washington N. Drug delivery to the larger intestine. In: Wilson CG, Washington N, eds. Physiological Pharmaceutics: Biological Barriers to Drug Absorption. Chichester, England: Ellis Horwood; 1989:91-108.
3. Hill MJ, Drasar BS. The normal colonic bacterial flora. Gut. 1975;16:318-323.
4. Gustafsson BE. The physiological importance of the colonic microflora. Scand J Gastroenterol. 1982;77(suppl):117-131.
5. Drasar BS, Hill MJ. Human Intestinal Flora. London, England: Academic Press; 1974:9-50.
6. Gorbach SL. Intestinal flora. Gastroenterology. 1971;60:1110-1129.
7. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990;11:465-475.
8. Simon GL, Gorback SL. Bacteriology of the colon. In: Bustos-Fernandez L, ed. Colon Structure and Function. New York, NY: Plenum Press; 1983:103-114.
9. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29:1035-1041.
10. Avery GS, Davies EF, Brogden RN. Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action in portal system encephalopathy. Drugs. 1972;4:7-48.
11. Tomlin J, Read NW. The relation between bacterial degradation of viscous polysaccharides and stool output in human beings. Br J Nutr. 1988;60:467-475.
12. Raimundo AH, Evans DF, Rogers J, Silk DBA. Gastrointestinal pH profiles in ulcerative colitis. Gastroenterology. 1992;104:A681.
13. Kaus LC, Fell JT, Sharma H, Taylor DC. On the intestinal transit of a single non-disintegration object. Int J Pharm. 1984;14:143-148.
14. Davis SS, Hardy JG, Stockwell A, Taylor MJ, Whalley DR, Wilson CG. The effect of food on gastrointestinal transit of pellets and an osmotic device (Osmet). Int J Pharm. 1984;21:331-340.
15. Wilson CG, Washington N, Greaves JL, Rees JA, Sempik AK, Lampard JF. Bimodal release of ibuprofen in a sustained release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int J Pharm. 1989;50:155-161.
16. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27:886-892.
17. Bararow L, Spiller RC, Wilson CG. Pathological influences on colonic motility: implications for drug delivery. Adv Drug Deliv Rev. 1991;7:201-220.
18. Weber MP, Stambouli F, Martin LJ, Dumon HJ, Biourge VC, Nguyen PG. Influence of age and body size on gastrointestinal transit time of radiopaque markers in healthy dogs. Am J Vet Res. 2002;63(5):677-682.
19. Tuleu C, Andrieux C, Boy P, Chaumeil JC. Gastrointestinal transit of pellets in rats: effect of size and density. Int J Pharm. 1999;180(1):123-131.
20. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15(11):1745-1751.
21. Metcalf AM, Phillips SF, Zinsmeister AR, MacCart RL, Beart RW, Walff BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92:40-47.
22. Hinds JP, Stoney B, Wald A. Does gender or the menstrual cycle affect colonic transit? Am J Gastroenterol. 1989;84:123-126.
23. Khosla R, Davis SS. Gastric emptying and small and large bowel transit of non-disintegrating tablets in fasted subjects. Int J Pharm. 1989;52:1-10.
24. Krishnaiah YSR, Satyanarayana S, Ramaprasad YV, Rao SN. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release. 1998;55:245-252.
25. Davis SS, Washington N, Parr GD, et al. Relationship between the appearance of oxprenolol in the systemic circulation and the location of an oxprenolol 16/260-drug delivery system within the gastrointestinal tract as determined by scintigraphy. Br J Clin Pharmacol. 1988;26:435-443.
26. Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM, Tucker RL. Unprepared human colon does not discriminate between solids and liquids. Am J Physiol Gastrointest Liver Physiol. 1991;260(23):G13-16.
27. Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol Gastrointest Liver Physiol. 1990;258:G856-G862.
28. Parker G, Wilson CG, Hardy JG. The effect of capsule size and density on transit through the proximal colon. J Pharm Pharmacol. 1988;40:376-377.
29. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol. 1985;37:874-877.
30. Watts PJ, Barrow L, Steed KP, et al. The transit rate of different sized model dosage forms through the human colon and the effect of lactulose induced catharsis. Int J Pharm. 1992;87:215-221.
31. Adkin DA, Davis SS, Sparrow RA, Wilding RA. Colonic transit of different sized tablets in healthy subjects. J Control Release. 1993;23:147-156.
32. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16(3):603-612.
33. Hu Z, Mawatari S, Shibata N, et al. Application of a biomagnetic system to the evaluation of gastrointestinal pressure-controlled colon delivery capsules in human subjects. Pharm Res. 2000;17:160-167.
34. Price JMC, Davis SS, Wilding IR. The effect of fiber on gastrointestinal transit times in vegetarians and omnivores. Int J Pharm. 1991;76:123-131.
35. Price JMC, Davis SS, Wilding IR, Sparrow RA. The effect of meal composition on gastro-colonic response: implications for drug delivery to the colon. Pharm Res. 1993;10:722-726.
36. Guimaraes EV, Goulart EM, Penna FJ. Dietary fiber intake, stool frequency and colonic transit time in chronic functional constipation in children. Braz J Med Biol Res. 2001;34(9):1147-1153.
37. Bennink R, Peeters M, Van den Maegdenbergh V, et al. Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women. Eur J Nucl Med. 1999;26(12):1560-1566.
38. Brunton L. Drugs affecting gastrointestinal function. In: Goodman LS, Gilman A eds. The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw Hill; 1996:901-936.
39. Tremaine WJ. Update: inflammatory bowel disease.Compr. Ther 1989; 15(2):17-21.
40. Thompson WG. Irritable bowel syndrome. In: Phillips SF, Femberton JH, Shorter G, eds. The Large Intestine: Physiology, Pathophysiology, and Disease. New York, NY: Raven Press; 1991.
41. Hardy JG, Davis SS, Khosla R, Robertson CS. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharm. 1988;48:79-82.
42. Barrow L, Steed KP, Spiller RC, et al. Scintigraphic demonstration of colonic transit by lactulose and its modification by gelling agents. Gastroenterology. 1992;103:1167-1173.
43. Barrow L, Steed KP, Spiller RC, et al. Quantitative non-invasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in men. Dig Dis Sci. 1993;38:996-1003.
44. Gutierrez C, Marco A, Nogales A, Tebar R. Total and segmental colonic transit time and anorectal manometry in children with chronic idiopathic constipation. J Pediatr Gastroenterol Nutr. 2002;35(1):31-38.
45. Law NM, Bharucha AE, Zinsmeister AR. Rectal and colonic distension elicit viscerovisceral reflexes in humans. Am J Physiol Gastrointest Liver Physiol. 2002;283(2):G384-G389.
46. Ron Y, Leibovitz A, Monastirski N, Habot B, Segal R. Colonic transit time in diabetic and nondiabetic long-term care patients. Gerontology. 2002;48(4):250-253.
47. Clemens CH, Samsom M, Van Berge Henegouwen GP, Fabri M, Smout AJ. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2002;16(5):993-1002.
48. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759-767.
49. Ron Y, Wainstein J, Leibovitz A, et al. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2002;57(2):M111-M114.
50. Wang SJ, Lan JL, Lan JL, et al. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21(4):271-274.
51. Smith PL, Wall DA, Gochoco CH, Wilson G. Oral absorption of proteins and peptides. Adv Drug Deliv Rev. 1992;8:253-290.
52. Wilson CG, Washington C, Washington N. Small intestine: transit and absorption of drugs. In: Wilson CG, Washington N, eds. Physiological Pharmaceutics: Biological Barriers to Drug Absorption. Chichester, England: Ellis Horwood; 1989:71-90.
53. Taylor DC, Lynch J, Leahy DE. Models for intestinal permeability to drugs. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester, England: Ellis Harwood; 1989:133-145.
54. Brockmeier D, Grigoleit HG, Leonhardt H. Absorption of glibenclamide from different sites of gastrointestinal tract. Eur J Clin Pharmacol. 1985;29:193-197.
55. Gleiter CH, Antonin KH, Bieck P, Godbillon J, Schonleber W. Colonoscopy in the investigation of drug absorption in healthy volunteers. Gastrointest Endosc. 1985;31:71-73.
56. Staib AH, Loew D, Harder S, Grayl EH, Pfab R. Measurement of theophylline absorption from different regions of gastrointestinal tract using a remote controlled device. Eur J Clin Pharmacol. 1986;9:95-97.
57. Godbillon J, Evard D, Vidon N, et al. Investigation of drug absorption from the gastrointestinal tract of man, III: metoprolol in the colon. Br J Clin Pharmacol. 1985;19:113S-118S.
58. Antonin KH, Bieck P, Scheurlen M, Jedrychowski V, Malchow H. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Br J Clin Pharmacol. 1985;19:137S-142S.
59. Bieck PR. Drug absorption from the human colon. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester, England: Ellis Horwood; 1989:147-159.
60. Brockmeier D, Grigoleit HG, Leonhardt H. The absorption of piretanide from the gastrointestinal tract is site dependent. Eur J Clin Pharmacol. 1986;30:79-82.
61. Wilson CG, Washington N, Greaves JL, Washington C, Hoadley T, Sims EE. Predictive modeling of the behaviour of a controlled release buflomedil hydrochloride formulation using scintigraphic and pharmacokinetic data. Int J Pharm. 1991;72:79-86.
62. Riley SA, Kim M, Sutcliffer F, Rowland M, Turnberg LA. Absorption of polar drugs following caecal instillation in healthy volunteers. Aliment Pharmacol Ther. 1992;6:701-706.
63. Erlich BE, Diamond JM. Lithium absorption: implications for sustained release lithium preparations. Lancet. 1983;1:306.
64. Ishibashi T, Ikegami K, Kubo H, Kobayashi M, Mizobe M, Yoshino H. Evaluation of colonic absorbability of drugs in dogs using a novel colon targeted delivery capsule (CTDC). J Control Release. 1999;59:361-376.
65. Schipper NGM, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drug, II: mechanism of absorption enhancement. Pharm Res. 1997;14(7):923-930.
66. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Deliv Rev. 1997;28:253-273.
67. Wilson G, Hassan IF, Din CJ, Shah R, Mackay MW, Artursson P. Transport and permeability properties of human Caco 2-cells: an in vitro model of the intestinal epithelial cell barrier. J Control Release. 1990;11:25-40.
68. Antonin KH, Saano V, Bieck P, et al. Colonic absorption of human calcitonin in man. Clin Sci. 1992;83:627-631.
69. Hastewell J, Antonin KH, Fox R, Mackay M. The colonic absorption of human calcitonin: the effects of increasing local concentration and co-administration with a protease inhibitor. Int J Pharm. 1995;126:245-251.
70. Antonin KH, Rak R, Bieck PR, et al. The absorption of human calcitonin from the transverse colon of man. Int J Pharm. 1996;130:33-39.
71. Hastewell J, Lynch S, Fox R, Williamson I, Skelton-Stroud P, Mackay M. Enhancement of human calcitonin absorption across the rat colon in vivo. Int J Pharm. 1994;101:115-120.
72. Gwinup G, Elias AN, Domurat ES. Insulin and c-peptide levels following oral administration of insulin in intestinal enzyme protected capsules. Gen Pharmacol. 1991;22:243-246.
73. Tozaki M, Komoike J, Maruyama T, Terabe A, Suzuki T. Chitosan capsule for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci. 1997;86(9):1016-1021.
74. Bernkop-Schnurch A, Scerbe-Saiko A. Synthesis and in vitro evaluation of chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins. Pharm Res. 1998;15(2):263-269.
75. Bernkop-Schnurch A, Krajicek ME. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J Control Release. 1998;50:215-223.
76. Hosny EA. Relative hypoglycemia of rectal insulin suppositories containing deoxycholic acid, sodium taurocholate polycarbophil and their combination in diabetic rabbits. Drug Dev Ind Pharm. 1999;25(6):745-752.
77. Lloyd AW, Hodges NA, Martin GP, Soozandehfat SH. Azo reduction is mediated by enzymatically generated low molecular weight electron carriers. J Pharm Pharmacol. 1993;45:21P
78. Jarnerot G. Newer 5-aminosalicylic acid drugs in chronic inflammatory bowel disease. Drugs. 1989;37:73-86.
79. Campbell DES, Berlingdh T. Pharmacology of olsalazine. Scand J Gastroenterol. 1988;23(suppl 148):7-12.
80. Sandberg-Gertzen H, Ryde M, Jarnerot G. Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention, a follow up study. Scand J Gastroenterol. 1988;23(suppl 148):48-50.
81. Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand J Gastroenterol. 1988;23(suppl 148):40-44.
82. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogues, ipsalazide and balsalazide. Dig Dis Sci. 1983;28:609-716.
83. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233:1081-1084.
84. Van Den Mooter G, Samyn C, Kinget R. Azo polymers for colon-specific drug delivery. Int J Pharm. 1992;87:37-46.
85. Van Den Mooter G, Samyn C, Kinget R. Azo polymers for colon-specific drug delivery, II: influence of the type of azo polymer on the degradation by intestinal microflora. Int J Pharm. 1993;97:133-139.
86. Schacht E, Gavaert A, Kenawy ER, et al. Polymers for colon-specific drug delivery. J Control Release. 1996;39:327-338.
87. Kimura Y, Makita Y, Kumagai T, et al. Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and application as a drug delivery system. Polymer. 1992;33:5294-5299.
88. Kopecek J, Kopeckova P, Brondsted H, et al. Polymers for colon-specific drug delivery. J Control Release. 1992;19:121-130.
89. Kakoulides EP, Smart JD, Tsibouklis J. Azo cross-linked poly (acrylic acid) for colonic delivery and adhesion specificity: synthesis and characterization. J Control Release. 1998;52:291-300.
90. Sakuma S, Lu Z, Kopeckova P, Kopecek J. Biorecognizable HPMA copolymer drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release. 2001;75:365-379.
91. Maris B, Verheyden L, Van Reeth K, et al. Synthesis and characterization of inulin-azo hydrogels designed for colon targeting. Int J Pharm. 2001;213(1-2):143-152.
92. Schacht E, Wilding IR. Process for the preparation of azo and/or disulphide containing polymers. US Patent 5 407 682. April 18, 1995.
93. Friend DR, Tozer TN. Drug glycosides in oral colon-specific drug delivery. J Control Release. 1992;19:109-120.
94. Kimura T, Yamaguchi T, Kurosaki Y, et al. Design and evaluation of colonic mucosa-specific pro-antidrugs for oral treatment of ulcerative colitis. Proc Int Symp Control Release Bioact Mater. 1991;18:427-428.
95. Milojevic S, Newton JM, Cummings JH, et al. Amylose as coating for drug delivery to the colon: preparation and in vitro evaluation using 5ASA pellets. J Control Release. 1996;38:75-84.
96. Milojevic S, Newton JM, Cummings JH, et al. Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using glucose pellets. J Control Release. 1996;38:85-94.
97. Siew LF, Basit AW, Newton JM. The potential of organic based amylose-ethylcellulose film coatings as oral colon-specific drug delivery systems. AAPS Pharm Sci Tech. 2000;1(3):article 22.
98. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. An evaluation of pectin as a carrier for drug targeting to the colon. J Control Release. 1993;26:213-220.
99. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. Studies on pectin formulations for colonic drug delivery. J Control Release. 1994;30:225-232.
100. Wakerly Z, Fell JT, Attwood D, Parkins D. Pectin/ethyl cellulose film coating formulations for colonic drug delivery. Pharm Res. 1996;13:1210-1212.
101. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharm Res. 1993;10:258-263.
102. Adkin DA, Kenyon CJ. The use of scintigraphy to provide proof of concept for novel polysaccharide preparation designed for colonic drug delivery. Pharm Res. 1997;14(1):103-107.
103. Munjeri O, Collett JH, Fell JT. Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. J Control Release. 1997;46:273-278.
104. Macleod GS, Fell JT, Collett JH, Sharma HL, Smith AM. Selective drug delivery to the colon using pectin:chitosan:hydroxpropylmethylcellulose film coated tablets. Int J Pharm. 1999;187(2):251-257.
105. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for the colonic delivery of model drug ropivacain. Eur J Pharm Sci. 2000;10(1):43-52.
106. Semde R, Amighi K, Devleeschouwer V, Moes AJ. Studies of Pectin HM/Eudragit RL/Eudragit NE film coating formulations intended for colonic drug delivery. Int J Pharm. 2000;197:181-192.
107. Semde R, Amighi K, Devleeschouwer MJ, Moes AJ. Effect of pectinolytic enzymes on the theophylline release from the pellets coated with water insoluble polymers containing Pectin HM or calcium pectinate. Int J Pharm. 2000;197:169-179.
108. Pai CM, Lim CB, Park CM, Park HN, Seomoon G. In vitro, in situ evaluation for colon-targeted budesonide tablet coated with the mixture of pectin/galactomannan. Proc Int Symp Control Release Bioact Mater. 2002;29:490-491.
109. Turkogulu M, Ugurlu T. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur J Pharm Biopharm. 2002;53(1):65-73.
110. Kenyon C, Nardi R, Wong D, Hooper G, Wilding I, Friend D. Colonic delivery of dexamethasone: a pharmacoscintigraphic clinical evaluation. Proc Int Symp Control Release Bioact Mater. 1996;23:553-554.
111. Lehmann KOR, Dreher KD. Methacrylate-galactomannan coating for colon-specific drug delivery. Proc Int Symp Control Release Bioact Mater. 1991;18:331-332.
112. Krishnaiah YSR, Satyanarayana S, Prasad YVR. Studies of guar gum compression coated 5-ASA tablets for colon-specific drug delivery. Drug Dev Ind Pharm. 1999;25(5):651-657.
113. Gliko-Kabir I, Yagen B, Penhasi A, Rubinstein A. Phosphated cross-linked guar for colon-specific drug delivery: preparation and physicochemical characterization. J Control Release. 2000;63:121-127.
114. Krishnaiah YSR, Satyanarayana SA, Karthikeyan RS. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target. 2002;10(3):247-254.
115. Hirsch S, Schelilmann K, Kolter K, Betzing J, Bauer KH. In vitro testing of cross linked galactomannan coated tablets for site-specific drug delivery to the colon. Proc Int Symp Control Release Bioact Mater. 1991;18:331-332.
116. Rubinstein A, Nakar D, Sintov A. Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat caecal content. Pharm Res. 1991;9(2):276-278.
117. Bronsted H, Andersen C, Hovgaard L. Cross linked dextran: a new capsule material for colon targeting of drugs. J Control Release. 1998;53:7-13.
118. Tozaki H, Odoriba T, Okada N, et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release. 2002;82(1):51-61.
119. Takaya T, Ikeda C, Imagawa N, Niwa K, Takada K. Development of a colon delivery capsule and pharmacological activity of recombinant human granulocyte colony-stimulating factor in beagle dogs. J Pharm Pharmacol. 1995;47:474-478.
120. Hu Z, Kimura G, Mawatari S, et al. Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsule prepared by coating machine and in human subjects. J Pharm Pharmacol. 2000;52:1187-1193.
121. Hu Z, Kimura G, Mawatari S, Shimokawa T, Yoshikawa Y, Takada K. New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs. J Control Release. 1998;56:293-302.
122. Shibata N, Ohno T, Shimokawa T, et al. Application of pressure-controlled colon delivery capsules to oral administration of glycyrrhizin in dogs. J Pharm Pharmacol. 2001;53:441-447.
123. Healy JNC. Enteric coatings and delayed release. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester, England: Ellis Horwood; 1989:83-96.
124. Hardy JG, Healey JNC, Reynolds JR. Evaluation of enteric coated delayed release 5ASA tablets in patients with IBD. Aliment Pharmacol Ther. 1987;1:273-280.
125. Ashford M, Fell JT, Attwood D, Woodhead PJ. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm. 1993;91:241-245.
126. Ashford M, Fell JT, Attwood D, Woodhead PJ, Sharma H. An in vivo investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm. 1993;95:193-199.
127. Watts P. Colonic drug delivery composition. SU Patent 6 228 396. May 21, 2001.
128. Hosny EA, Ghilzai NMK, Najar TA, Elmazar MMA. Hypoglycemic effect of oral insulin in diabetic rabbits using pH dependent coated capsules containing sodium salicylate without and with sodium cholate. Drug Dev Ind Pharm. 1998;24(3):307-311.
129. Larenzo-Lamosa ML, Remanan LC, Vila-Jate JL, Alonso MJ. Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release. 1998;52:109-118.
130. Khan MZI, Prebeg Z, Kurjakovic N. A pH dependent colon targeted oral drug delivery system using methacrylic acid copolymers. J Control Release. 1999;58:215-222.
131. Khan MZI, Stedul HP, Kurjakovic N. A pH dependent colon targeted oral drug delivery system using methacrylic acid copolymers, II: manipulation of drug release using Eudragit L 100 and Eudragit S 100 combinations. Drug Dev Ind Pharm. 2000;26(5):549-554.
132. Rodriguez M, Vila-Jato JL, Torres D. Design of new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Release. 1998;55(1):67-77.
133. Chiu HC, Hsiue GH, Lee YP, Huang LW. Synthesis and characterization of pH sensitive dextran hydrogels as a potential colon-specific drug delivery system. J Biomater Sci Polym Ed. 1999;10(5):591-608.
134. Leopold CS, Eikeler D. Basic coating polymers for the colon-specific drug delivery in inflammatory bowel diseases. Drug Dev Ind Pharm. 2000;26(12):1239-1246.
135. Krogars K, Heinamaki J, Vesalahti J, Marvola M, Antikainen O, Yliruusi J. Extrusion- spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int J Pharm. 2000;199(2):187-194.
136. Rudolph MW, Klein S, Beckert TE, Petereit H, Dressman JB. A new 5-aminosalicylic acid multiunit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;53(3):183-190.
137. Jeong Y, Prasad R, Ohno T, et al. Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine. J Pharm Pharmacol. 2001;53:1079-1085.
138. Cole ET, Scott RA, Connor AL, et al. Enteric coated HPMC capsule designed to achieve intestinal targeting. Int J Pharm. 2002;231(1):83-95.
139. Scherer DDS. Develops alarm clock dose formulation. Pharm J. 1991;247:138.
140. . Binns JS, Bakhshaee M, Miller CJ, Stevens HNE. Application of a pH dependent PEG based hydrogel to afford pulsatile drug delivery. Proc Int Symp Control Release Bioact Mater. 1993;20:226-227.
141. Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. GI transit and systemic absorption of captopril from a pulsed release formulation. Pharm Res. 1992;9:654-657.
142. Binns J, Stevens HNE, McEvwen J, et al. The tolerability of multiple doses of Pulsincap capsules in healthy volunteers. J Control Release. 1996;38:151-158.
143. Pozzi F, Furlani P, Gazzaniga A, Davis SS, Wilding IR. The Time Clock system: a new oral dosage form for fast and complete release of drug after pre-determined lag time. J Control Release. 1994;31:99-108.
144. Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayed release system for colon-specific delivery. Int J Pharm. 1994;108:77-83.
145. Gazzaniga A, Busetti C, Moro L, Crimella T, Sangalli ME, Giordano F. Evaluation of low viscosity HPMC as retarding coating material in the preparation of a time-based oral colon-specific delivery system. Proc Int Symp Control Release Bioact Mater. 1995;22:242-243.
146. Theeuwes F, Wong P, Berkoth TL, Fox DA. Osmotic systems for colon targeted drug delivery. In: Biech P, ed. Colonic Drug Absorption and Metabolism. New York, NY: Marcel Dekker; 1993:137-158.
147. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated time release press coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm. 2000;204:7-15.
148. Gupta VK, Beckert TE, Price JC. A novel pH and time based multiunit potential colonic drug delivery system, I: development. Int J Pharm. 2001;213:88-91.
149. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzanigab A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Release. 2001;73(1):103-110.
150. Ibrahim E. Oral delayed-release system based on Zn-Pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm. 2002;232:199-211.
151. Watanabe S, Kawai H, Katsuma M. Fukui M. Colon-specific drug release system. US patent 6 368 629. April 9, 2002.
152. Takemura S, Watanabe S, Katsuma M, Fukui M. Human gastrointestinal transit study of a novel colon delivery system (CODES) using gamma scintigraphy. Proc Int Symp Control Release Bioact Mater. 2000;27(6301):1-2
153. Katsuma M. Colonic-specific drug delivery system (CODES). Paper presented at 5th US/Japan Symposium on Drug Delivery Systems; December 12-17, 1999. Lahaina, HI.
154. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosages forms through the small intestine. Gut. 1986;27:886-892.
155. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235:1-15.
156. Kinget R, Kalala W, Vervoort L, Mooter VD. Colonic drug targeting. J Drug Target. 1998;6:129-149.
157. Rubinstein A. Approaches and opportunities in colon-specific delivery. Crit Rev Ther Drug Carrier Syst. 1995;12:101-149.